RecruitingPhase 2NCT04943198
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Sponsor
Anna Raciborska
Enrollment
25 participants
Start Date
Apr 1, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of vemurafenib in juvenile patients with histiocytosis resistant to conventional therapy and in whom the BRAF gene mutation has been found.
Eligibility
Min Age: 1 YearMax Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Vemurafenib for people with histiocytosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 18 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVemurafenib
20 mg/kg/day
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04943198
Related Trials
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT0578692427 locations
Histiocytic Disorder Follow-up Study
NCT059152081 location
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
NCT049432111 location
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
NCT049432241 location
Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
NCT046656741 location